Immune response after primary and re-vaccination with different combined vaccines against measles, mumps, rubella

Vaccine

Volumn 18, Issue 14, 2000, Pages 1382-1392

  Tischer, A ^a   Gerike, E ^a  

^a ROBERT KOCH INSTITUTE   (Germany)

Author keywords

Humoral immune response; Measles; Mumps; Re vaccination; Rubella vaccines

Indexed keywords

MEASLES MUMPS RUBELLA VACCINE; UNCLASSIFIED DRUG;

ADOLESCENT; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; HUMAN; HUMORAL IMMUNITY; IMMUNOGENICITY; INFANT; MAJOR CLINICAL STUDY; MEASLES; MUMPS; PRIORITY JOURNAL; REVACCINATION; RUBELLA; SCHOOL CHILD; SEROCONVERSION;

ADOLESCENT; ADULT; ANTIBODIES, VIRAL; ANTIBODY FORMATION; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INFANT; MALE; MEASLES; MEASLES VACCINE; MEASLES VIRUS; MEASLES-MUMPS-RUBELLA VACCINE; MUMPS; MUMPS VACCINE; MUMPS VIRUS; RUBELLA; RUBELLA VACCINE; RUBELLA VIRUS; VACCINES, COMBINED;

EID: 0033962333     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(99)00397-7     Document Type: Article

References (53)

1. Wkly. Epidemiol. Rec. 71:1996;305-312.
2. Orenstein W.A., Markowitz L.E., Atkinson W.L., Hinman A.R. Worldwide measles prevention. Isr. J. Med. Sci. 30:1994;469-481.
3. Peltola H., Heinonen O.P., Valle M., Paunio M., Virtanen M., Karanko V., Cantell K. The elimination of indigenous measles, mumps, and rubella from Finland by a 12-year, two-dose vaccination program. N. Engl. J. Med. 331:1994;1398-1402.
4. Miller E., Goldacre M., Pugh S., Colville A., Farrington P., Flower A., Nash J., MacFarlane L., Tettmar R. Risk of aseptic meningitis after measles, mumps, and rubella vaccine in UK children. Lancet. 341:1993;979-983.
5. Forsey T., Bentley M.L., Minor P.D., Begg N. Mumps vaccines and meningitis. Lancet. 340:1992;980.
6. Gerike E., Rasch G. Masernschutzimpfung. Z. ärztl. Fortbild. 84:1990;369-371.
7. Dopatka H.D., Giesendorf B. Single point quantification of antibody by ELISA without need of a reference curve. J. Clin. Lab. Analysis. 6:1992;417-422.
8. Tischer A., Gerike E. Einpunktquantifizierung von IgG-Antikörpern mit dem Enzymimmunoassay im Vergleich zu klassischen Techniken am Beispiel von Masern, Mumps, Röteln. Lab. Med. 18:1994;501-507.
9. Bellini W.J., Rota J.S., Rota P.A. Virology of measles virus. J. Infect. Dis. 170:1994;15-23.
10. Popow-Kraupp T., Kundi M., Ambrosch F., Vanura H., Kunz C. A controlled trial for evaluating two live attenuated mumps-measles vaccines (Urabe Am 9-Schwarz and Jeryl Lynn-Moraten) in young children. J. Med. Virol. 18:1986;69-79.
11. Boulianne N., De Serres G., Ratnam S., Ward B.J., Joly J.R., Duval B. Measles, mumps, and rubella antibodies in children 5-6 years after immunization: effect of vaccine type and age at vaccination. Vaccine. 13:1995;1611-1616.
12. Hussey G., Goddard E.A., Hughes J., Ryon J.J., Kerran M., Carelse E., Strebel P.M., Markowitz L.E., Moodie J., Barron P., Latief Z., Sayed R., Beatty D., Griffin D.E. The effect of Edmonston-Zagreb and Schwarz measles vaccines on immune responses in infants. J. Infect. Dis. 173:1996;1320-1326.
13. Cutts T.F., Grabowsky M., Markowitz L.E. The effect of dose and strain of live attenuated measles vaccines on serological responses in young infants. Biologicals. 23:1995;95-106.
14. Rota J.S., Wang Z.D., Rota P.A., Bellini W.J. Comparison of sequences of the H, F, and N coding genes of measles virus vaccine strains. Virus Research. 31:1994;317-330.
15. Heider A., Santibanez S., Tischer A., Gerike E., Tikhonova N., Ignatyev G., Mrazova M., Enders G., Schreier E. Comparative investigation of the long non-coding M-F genome region of wild-type and vaccine measles viruses. Arch. Virol. 142:1997;2521-2528.
16. Chen R.T., Markowitz L.E., Albrecht P., Stewart J.A., Mofenson L.M., Preblud S.R., Orenstein W.A. Measles antibody: reevaluation of protective titers. J. Infect. Dis. 162:1990;1036-1042.
17. Samb B., Aaby P., Whittle H.C., Seck A.M., Rahman S., Bennett J., Markowitz L., Simondon F. Serologic status and measles attack rates among vaccinated and unvaccinated children in rural Senegal. Pediatr. Infect. Dis. J. 14:1995;203-209.
18. Friedman M.G., Romanova S., Galil A., Sarov B., Dagan R. Comparison of a commercial ELISA kit and a neutralization assay for assessment of humoral immunity to measles virus. Serodiagnosis and Immunotherapy in Infectious Disease. 8:1997;131-135.
19. Ratnam S., Gadag V., West R., Burris J., Oates E., Stead F., Boulianne N. Comparison of commercial enzyme immunoassay kits with plaque reduction neutralization test for detection of measles virus antibody. Journal of Clinical Microbiology. 33:(4):1995;811-815.
20. Christenson B., Böttiger M. Measles antibody: comparison of long-term vaccination titres, early vaccination titres and naturally acquired immunity to and booster effects on the measles virus. Vaccine. 12:1994;129-133.
21. Diaz-Ortega J.L., Forsey T., Clements C.J., Milstien J. The relationship between dose and response of standard measles vaccines. Biologicals. 22:1994;35-44.
22. Pederson I.R., Mordhorst C.H., Glikmann G., von Magnus H. Subclinical measles infection in vaccinated seropositive individuals in arctic Greenland. Vaccine. 7:1989;345-348.
23. Bin D., Zhihui C., Qichang L., Ting W., Chengyin G., Xingzi W., Hanhua F., Yongzhong X. Duration of immunity following immunization with live measles vaccine: 15 years of observation in Zhejiang Province, China. Bull. World Health Organ. 69:1991;415-423.
24. Johnson H., Hillary I.B., McQuoid G., Gilmer B.A. MMR vaccination, measles epidemiology and sero-surveillance in the Republic of Ireland. Vaccine. 13:1995;533-537.
25. Cohn M.L., Robinson E.D., Faerber M., Thomas D., Geyer S., Peters S., Martin M., Martin A., Sobel D., Jones R., Larkin L., Richert J.R. Measles vaccine failures: lack of sustained measles-specific immunoglobulin G responses in revaccinated adolescents and young adults. Pediatr. Infect Dis. J. 13:1994;34-38.
26. Watson J.C., Pearson J.A., Markowitz L.E., Baughman A.L., Erdman D.D., Bellini W.J., Baron R.C., Fleming D.W. An evaluation of measles revaccination among school-entry-aged children. Pediatrics. 97:(5):1996;613-618.
27. Calvert N., Cutts F., Irving R., Brown D., Marsh J., Miller E. Measles immunity and response to revaccination among secondary school children in Cumbria. Epidemiol. Infect. 116:1996;65-70.
28. Gerike E., Kirchner W., Pöhle W., Tischer A. Untersuchungen zur Frage einer Wiederimpfung gegen Masern. Z. Ges. Hyg. 29:1983;62-65.
29. Gay N., Ramsay M., Cohen B., Hesketh L., Morgan-Capner P., Brown D., Miller E. The epidemiology of measles in England and Wales since the 1994 vaccination campaign. Commun. Dis. Rep. 7:1997;17-21.
30. Poland G.A., Jacobson R.M., Thampy A.M., Colbourne S.A., Wollan P.C., Lipsky J.J., Jacobson S.J. Measles reimmunization in children seronegative after initial immunization. J. Am. Med. Assoc. 227:1997;1156-1164.
31. Christenson B., Böttiger M. Methods for screening the naturally acquired and vaccine-induced immunity to the measles virus. Biologicals. 18:1990;207-211.
32. Balraj V., Miller E. Complications of mumps vaccines. Rev. Med. Vir. 5:1995;219-227.
33. Glück R., Hoskins J.M., Wegmann A., Just M., Germanier R. Rubini, a new live attenuated mumps vaccine virus strain for human diploid cells. Develop. Biol. Standard. 65:1985;29-35.
34. Vesikari T., André F.E., Simoen E., Florent G., Ala-Laurila E.L., Heikkinen A., Kuusinen H., Terho A. Evaluation in young children of the Urabe Am 9 strain of live attenuated mumps vaccine in comparison with the Jeryl Lynn strain. Acta. Paediatr. Scand. 72:1983;37-40.
35. Miller E., Hill A., Morgan-Capner P., Forsey T., Rush M. Antibodies to measles, mumps and rubella in UK children 4 years after vaccination with different MMR vaccines. Vaccine. 13:1995;799-813.
36. Schwarzer S., Reibel S., Lang A., Struck M.M., Finkel B., Gerike E., Tischer A., Gassner M., Glück R., Stück B., Cryz S.J. Jr. Safety and characterization of the immune response engendered by two combined measles, mumps and rubella vaccines. Vaccine. 16:1998;298-304.
37. Just M., Berger R., Glück R., Wegmann A. Evaluation of a combined vaccine against measles-mumps-rubella produced on human diploid cells. Develop. Biol. Standard. 65:1985;25-27.
38. Berger R., Just M., Glück R. Interference between strains in live virus vaccines I: combined vaccination with measles, mumps and rubella vaccine. Biol. Stand. 16:1988;269-273.
39. Briss P.A., Fehrs L.J., Parker R.A., Wright P.F., Sannella E.C., Hutcheson R.H., Schaffner W. Sustained transmission of mumps in a highly vaccinated population: assessment of primary vaccine failure and waning vaccine-induced immunity. J. Infect. Dis. 169:1994;77-82.
40. Cheek J.E., Baron R., Atlas H., Wilson D., Crider R. Mumps outbreak in a highly vaccinated school population. Arch. Pediatr. Adolesc. Med. 149:1995;774-778.
41. Gay N., Miller E., Hesketh L., Morgan-Capner P., Ramsay M., Cohen B., Brown D. Mumps surveillance in England and Wales supports introduction of two dose vaccination schedule. Commun. Dis. Rep. 7:1997;21-25.
42. Dias J.A., Cordeiro M., Afzal M.A., Freitas M.G., Morgado M.R., Silva J.L., Nunes L.M., Lima M.G., Avilez F. Mumps epidemic in Portugal despite high vaccine coverage - preliminary report. Eurosurveillance. 1:1996;25-28.
43. Toscani L., Batou M., Bouvier P., Schlaepfer A. Comparaison de l’efficacité de differentes souches de vaccin ourlien: Une enquête en milieu scolaire. Soz. Präventivmed. 41:1996;341-347.
44. Germann D., Ströhle A., Eggenberger K., Steiner C.A., Matter L. An outbreak of mumps in a population partially vaccinated with the Rubini strain. Scand. J. Infect. 28:1996;235-238.
45. Broliden K., Abreu E.R., Arneborn M., Böttiger M. Immunity to mumps before and after MMR vaccination at 12 years of age in the first generation offered the two-dose immunization programme. Vaccine. 16:1998;323-327.
46. Davidkin I., Valle M., Julkunen I. Persistence of anti-mumps virus antibodies after a two-dose MMR vaccination. A nine-year follow-up. Vaccine. 13:1995;1617-1622.
47. Christenson B., Böttiger M. Methods for screening the naturally acquired and vaccine-induced immunity to the mumps virus. Biologicals. 18:1990;213-219.
48. Skendzel L.P. Rubella immunity. Defining the level of protective antibody. Am. J. Clin. Pathol. 106:1996;170-174.
49. O’Shea S., Corbett K.M., Barrow S.M., Banatvala J.E., Best J.M. Rubella reinfection; role of neutralising antibodies and cell-mediated immunity. Clin. Diagn. Virol. 2:1994;349-358.
50. Matter L., Kogelschatz K., Germann D. Serum levels of Rubella virus antibodies indicating immunity: response to vaccination of subjects with low or undetectable antibody concentrations. J. Infect. Dis. 175:1996;749-755.
51. Christenson B., Böttiger M. Long-term follow-up study of rubella antibodies in naturally immune and vaccinated young adults. Vaccine. 12:1994;41-45.
52. Böttiger M. Immunity to rubella before and after vaccination against measles, mumps and rubella (MMR) at 12 years of age of the first generation offered MMR vaccination in Sweden at 18 months. Vaccine. 13:1995;1759-1762.
53. Miller E., Waight P., Gay N., Ramsay M., Vurdien J., Morgan-Capner P., Hesketh L., Brown D., Tookey P., Peckham C. The epidemiology of rubella in England and Wales before and after the 1994 measles and rubella vaccination campaign: fourth joint report from the PHLS and the National Congenital Rubella Surveillance Programme. Commun. Dis. Rep. 7:1997;26-32.